KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teladoc Health (TDOC) Operating Expenses (2016 - 2025)

Teladoc Health's Operating Expenses history spans 12 years, with the latest figure at $678.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 1.52% year-over-year to $678.3 million; the TTM value through Dec 2025 reached $2.8 billion, down 22.21%, while the annual FY2025 figure was $2.8 billion, 22.21% down from the prior year.
  • Operating Expenses for Q4 2025 was $678.3 million at Teladoc Health, roughly flat from $678.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $7.2 billion in Q1 2022 and bottomed at $538.4 million in Q1 2021.
  • The 5-year median for Operating Expenses is $692.2 million (2023), against an average of $1.4 billion.
  • The largest annual shift saw Operating Expenses surged 1243.86% in 2022 before it tumbled 90.24% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $595.7 million in 2021, then skyrocketed by 647.61% to $4.5 billion in 2022, then plummeted by 84.38% to $695.6 million in 2023, then dropped by 0.99% to $688.7 million in 2024, then fell by 1.52% to $678.3 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Operating Expenses are $678.3 million (Q4 2025), $678.4 million (Q3 2025), and $686.3 million (Q2 2025).